AstraZeneca Acquires Takeda’s respiratory business


03 May 2016

AstraZeneca is an innovation-driven, global biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines. It operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. The company has recently announced that it has completed the acquisition of Takeda Pharmaceutical Company Limited’s core respiratory business.

The agreement was announced in December 2015, which includes the expansion of rights to roflumilast (marketed in the US as Daliresp and Daxas in other countries). This is the only approved oral PDE4 inhibitor for treating chronic obstructive pulmonary disease. AstraZeneca has marketed Daliresp in the US since the acquisition of the rights from Actavis in the first quarter of 2015.

AstraZeneca Acquires Takeda’s respiratory business last edit: 2016-05-11T18:00:41+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar